Ann: Atomo provides update on its HIV Rapid Test business, page-15

These announcements show steady growth in demand for AT1 product offering and are great as far as I am concerned (regardless of the SP direction). Especially any announcement relating to supply contracts for non-covid related products that the company offers!

The idea that you're going to see management ramp this stock like certain 'BNPL shares' is pointless, as it only bring short term volatility and adds to holders frustrations. If you're not willing to hold this stock in the bid for medium term capital gains and/or a possible future acquisitions by a larger pharma company, then get out.

In response to the whining about revenue updates, the company provides 4x a year, as per the listing rules. So you'll have one next month on the release of the half yearly results. In the mean time go out and get some fresh air and cease trolling the page day in day out for updates.